Jukka Westermarck
Turku, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
Correction: The PP2A regulator IER5L supports prostate cancer progression.
Journal: Cell death & disease
Published: July 22, 2025
Complex I drives glutamine-dependent TCA cycle to support viability of MYChigh breast cancer cells.
Journal: Cell reports
Published: May 30, 2025
LIMA1-alpha staining predicts curative intent surgery response in HPV negative head and neck cancer.
LIMA1-alpha staining predicts curative intent surgery response in HPV negative head and neck cancer.
Journal: EMBO molecular medicine
Published: October 21, 2024
NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition.
Journal: Oncogene
Published: May 30, 2024
The PP2A regulator IER5L supports prostate cancer progression.
Journal: Cell death & disease
Published: December 21, 2023
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Journal: EMBO molecular medicine
Published: September 04, 2023
CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response.
Journal: Trends in cancer
Published: July 14, 2023
Inhibition of adaptive therapy tolerance in cancer: is triplet mitochondrial targeting the key?
Journal: Molecular oncology
Published: February 03, 2023
RAS and PP2A activities converge on epigenetic gene regulation.
Journal: Life science alliance
Published: January 16, 2023
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
Journal: Molecular oncology
Published: November 23, 2022
SHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis.
Journal: Journal of cell science
Published: September 11, 2022
Last Updated: 09/26/2026